An Antipsychotic Patch
The Carlat Psychiatry Report, Volume 17, Number 11&12, November 2019
https://www.thecarlatreport.com/newsletter-issue/tcprv17n11-12/
Issue Links: Learning Objectives | Editorial Information
Topics: Antipsychotic | Asenapine | News of Note | Patch | Saphris | Secuado | Transdermal
Chris Aiken, MD.
Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.
Secuado, the first transdermal patch for schizophrenia, is newly approved version of asenapine (aka Saphris). It promises to reduce side effects and enhance adherence. However, it adds a new side effect of its own, and transdermal delivery isn’t clearly better than sublingual, which is how the older Saphris is absorbed.
You can't view details of this content, please login or buy subscription here